文献速递心律失常心力衰竭与心肌病

致心律失常性右心室心肌病:临床病程与心律失常风险预测因素

Arrhythmogenic Right Ventricular Cardiomyopathy: Clinical Course and Predictors of Arrhythmic Risk.
PubMed 文献 · J Am Coll Cardiol · 2016-01-01

本研究连续纳入301例致心律失常性右心室心肌病患者,采用Kaplan-Meier法调整延迟入组偏倚描述临床病程,Cox多因素分析确定5.8年随访期间危及生命心律失常事件(LAE)的预测因素,并比较匹配时间 intervals 内治疗前后LAE发生率评估疗效。结果显示LAE风险从青春期持续至高龄,21-40岁达峰;心房颤动、晕厥、诊断后剧烈运动、血流动力学稳定的持续性单形性室性心动过速及男性为预测因素;胺碘酮、β受体阻滞剂、索他洛尔或消融治疗前后LAE发生率无差异。

要点

  • LAE风险从青春期持续至高龄,21-40岁达峰,累积概率5年14%、10年23%、15年30%。
  • 心房颤动、晕厥、诊断后剧烈运动、血流动力学稳定的持续性单形性室速及男性预测LAE。
  • 胺碘酮、β受体阻滞剂、索他洛尔或消融治疗前后LAE发生率无差异。

主要发现

  • 出生至20岁首次LAE发生率为1.5/100人年,21-40岁为4.0/100人年,41-60岁为2.4/100人年。
  • 随访期间首次LAE累积概率5年14%、10年23%、15年30%。
  • LAE风险预测因素:心房颤动(HR 4.38;p=0.002)、晕厥(HR 3.36;p<0.001)、诊断后剧烈运动(HR 2.98;p=0.028)、血流动力学稳定的持续性单形性室速(HR 2.19;p=0.023)、男性(HR 2.49;p=0.012)。
  • 胺碘酮、β受体阻滞剂、索他洛尔或消融治疗前后LAE发生率无差异。
  • 81例患者接受植入式心律转复除颤器,34例成功除颤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a leading cause of sudden cardiac death, but its progression over time and predictors of arrhythmias are still being defined. OBJECTIVES: This study sought to describe the clinical course of ARVC and occurrence of life-threatening arrhythmic events (LAE) and cardiovascular mortality; identify risk factors associated with increased LAE risk; and define the response to therapy. METHODS: We determined the clinical course of 301 consecutive patients with ARVC using the Kaplan-Meier method adjusted to avoid the bias of delayed entry. Predictors of LAE over 5.8 years of follow-up were determined with Cox multivariable analysis. Treatment efficacy was assessed comparing LAE rates during matched time intervals. RESULTS: A first LAE occurred in 1.5 per 100 person-years between birth and age 20 years, in 4.0 per 100 person-years between ages 21 and 40 years, and in 2.4 per 100 person-years between ages 41 and 60 years. Cumulative probability of a first LAE at follow-up was 14% at 5 years, 23% at 10 years, and 30% at 15 years. Higher risk of LAE was predicted by atrial fibrillation (hazard ratio [HR]: 4.38; p = 0.002), syncope (HR: 3.36; p < 0.001), participation in strenuous exercise after the diagnosis (HR: 2.98; p = 0.028), hemodynamically tolerated sustained monomorphic ventricular tachycardia (HR: 2.19; p = 0.023), and male sex (HR: 2.49; p = 0.012). No difference was observed in the occurrence of LAE before and after treatment with amiodarone, beta-blockers, sotalol, or ablation. A total of 81 patients received an implantable cardioverter-defibrillator, 34 were successfully defibrillated. CONCLUSIONS: The high risk of life-threatening arrhythmias in patients with ARVC spans from adolescence to advanced age, reaching its peak between ages 21 and 40 years. Atrial fibrillation, syncope, participation in strenuous exercise after the diagnosis of ARVC, hemodynamically tolerated sustained monomorphic ventricular tachycardia, and male sex predicted lethal arrhythmias at follow-up. The lack of efficacy of antiarrhythmic therapy and the life-saving role of the implantable cardioverter-defibrillator highlight the importance of risk stratification for patient management.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Mazzanti A, Ng K, Faragli A, et al. Arrhythmogenic Right Ventricular Cardiomyopathy: Clinical Course and Predictors of Arrhythmic Risk. J Am Coll Cardiol. 2016. PMID: 27931611. doi:10.1016/j.jacc.2016.09.951

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。